Behavioral Economics Incentives to Support HIV Treatment Adherence in Sub-Saharan Africa

NCT ID: NCT03494777

Last Updated: 2024-03-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

331 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-11

Study Completion Date

2023-10-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will implement an intervention in a two-year randomized controlled trial (RCT) to establish efficacy on viral suppression as a biological endpoint, compare the effectiveness of two different modes of implementation (including one entirely based on readily available clinic data), and investigate cost-effectiveness. Participants in the first intervention group (T1, n=110) will be eligible for small lottery prizes based on timely clinic visits, and qualify for an annual lottery conditional if demonstrating viral suppression; those in the second group (T2, n=110) will draw prizes conditional on electronically measured adherence at each clinic visit, and also participate in an annual lottery that is conditional on high adherence throughout the year. The control group (n=110) will receive the usual standard of care. Assessments will be conducted at baseline and then every six months. Primary outcomes are undetectable viral load and electronically measured adherence.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is imperative to find ways to boost ART adherence in sub-Saharan Africa where adherence rates have been found to decline over time, and where treatment options such as second-line regimens are limited. A promising tool is the use of incentives based on insights from behavioral economics (BE) for healthy HIV-related behavior. The proposed R01 study is based on the results of the PI's R34 'Rewarding Adherence Program (RAP)' \[R34 MH096609\] that demonstrated feasibility and acceptability of incentives allocated by a drawing for HIV-related behaviors, and established preliminary efficacy. The current R01 study builds on these promising results with the aim to a) use viral loads as biological endpoints that were not included in the R34 for cost reasons; b) establish efficacy in a fully powered intervention as well as comparative efficacy of two different ways of implementing the incentives including one arm that has been adapted to changing clinical guidelines and can be implemented with readily available data from clinic records; and c) assess the cost effectiveness of these two implementation modes as a further input for policy-makers. The intervention is targeted at increasing the motivation of HIV clients who have been on ART for several years through the benefit and joy of prize drawings, thereby attempting to overcome the treatment 'fatigue' that can develop in the context of mundane, daily pill taking over the course of life-long treatment. Insights from behavioral economics suggest that such an intervention may be particularly effective for people with present bias (those who have a tendency to give in to short-term temptation at the cost of more long-term benefits) that was found to be prevalent among HIV clients in the R34 study. The intervention will be implemented among 330 adult clients in three groups: for the first intervention group, timely clinic attendance will constitute the eligibility criteria for participating in a prize drawing at each scheduled clinic visit; participants are also eligible for an annual prize drawing based on showing viral suppression. The second treatment group will be incentivized on demonstrated high ART adherence between clinic visits that also determine the winning chances at an annual prize drawing. The control group will receive the usual standard of care. All participants will receive MEMS caps to record adherence and assessments over 24 months (at baseline and every 6 months thereafter). The first Specific Aim will be to evaluate the effectiveness of the intervention; the second aim is to compare the relative effectiveness of the adherence-based arm and the arm directly incentivizing viral suppression that uses only data readily available in the clinic. The third Specific Aim is to perform a comparative cost-effectiveness analysis of the two intervention arms as a further policy input. If proven efficacious, the intervention as implemented in the newly adapted arm based on viral load suppression can be readily taken over by the clinic and scaled at low cost to other clinics.

In the study also 70 treatment initiating clients (in addition to the 330 treatment mature clients described above) will be recruited, but they will be excluded from the main analysis. \[Note on 9/7/2019: due to funding, we will not recruit this additional sample of treatment initiating clients\]

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV/AIDS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Randomized controlled trial with two intervention arms and a control group will receive an intervention for twelve months; those not showing viral suppression at month 12 will be randomized to either continue receiving the year 1 intervention for another twelve months, or receive an additional intervention component for twelve months.

The main analysis will be based on the sample of 330 treatment mature clients, from which the 70 treatment initiating clients will be excluded.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors
The investigator and outcomes assessor will be blinded to treatment assignment of study participants.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices.

Group Type NO_INTERVENTION

No interventions assigned to this group

Adherence-based incentivization

Participants will be eligible for prize drawings at every regular clinic visit based on high adherence as measured by MEMS-caps. In addition there will be an annual prize drawing that is conditional on showing high adherence over the course of the year.

This arm will receive the intervention 'Incentivization based on high adherence' and the intervention 'Annual adherence prize drawing' and (if eligible) the intervention 'Year 2 booster'.

Note: the 70 treatment initiating clients will all be assigned to this arm to receive preliminary data as to whether incentives may work for this group.

Group Type EXPERIMENTAL

Incentivization based on high adherence

Intervention Type BEHAVIORAL

When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month \>=90%, will participate in a prize drawing.

Annual adherence prize drawing

Intervention Type BEHAVIORAL

Participants will have a chance to take part in an annual drawing where eligibility is based on the average adherence during that year.

Year 2 booster

Intervention Type BEHAVIORAL

Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.

Viral suppression-based incentivization

Participants will be able to participate in prize drawings at every clinic visit where eligibility will be based on timely drug refills (that coincide with the clinic visits). Participants will also have a chance to enter a prize drawing at the end of every year if they show viral suppression.

This arm will receive the intervention 'Incentivization based on timely clinic visit' and the intervention 'Annual viral suppression-based prize drawing', and (if eligible) the intervention 'Year 2 booster'.

Group Type EXPERIMENTAL

Incentivization based on timely clinic visit

Intervention Type BEHAVIORAL

When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.

Annual viral suppression-based prize drawing

Intervention Type BEHAVIORAL

Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.

Year 2 booster

Intervention Type BEHAVIORAL

Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Incentivization based on high adherence

When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month \>=90%, will participate in a prize drawing.

Intervention Type BEHAVIORAL

Incentivization based on timely clinic visit

When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.

Intervention Type BEHAVIORAL

Annual adherence prize drawing

Participants will have a chance to take part in an annual drawing where eligibility is based on the average adherence during that year.

Intervention Type BEHAVIORAL

Annual viral suppression-based prize drawing

Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.

Intervention Type BEHAVIORAL

Year 2 booster

Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age or older
* at Mildmay clinic on ART for at least two years
* adherence problems in the last six months


* 18 years of age or older
* started on ART at Mildmay clinic within the last six months

Exclusion Criteria

* not able to understand the consent form and study procedures
* language other than Luganda or English
* not willing to consistently use the MEMS caps device for adherence measurement
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

Mildmay Uganda Limited

OTHER

Sponsor Role collaborator

RAND

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sebastian Linnemayr, PhD

Role: PRINCIPAL_INVESTIGATOR

RAND

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mildmay Uganda

Kampala, , Uganda

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Uganda

References

Explore related publications, articles, or registry entries linked to this study.

Wagner Z, Wang Z, Stecher C, Karamagi Y, Odiit M, Haberer JE, Linnemayr S. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda. J Int AIDS Soc. 2024 Aug;27(8):e26350. doi: 10.1002/jia2.26350.

Reference Type DERIVED
PMID: 39155425 (View on PubMed)

Linnemayr S, Wagner Z, Saya UY, Stecher C, Lunkuse L, Wabukala P, Odiit M, Mukasa B. Behavioral Economic Incentives to Support HIV Care: Results From a Randomized Controlled Trial in Uganda. J Acquir Immune Defic Syndr. 2024 Jul 1;96(3):250-258. doi: 10.1097/QAI.0000000000003420.

Reference Type DERIVED
PMID: 38534162 (View on PubMed)

MacCarthy S, Wagner Z, Saya U, Ghai I, Karamagi Y, Odiit M, Mukasa B, Linnemayr S. Food Insecurity During the COVID-19 Pandemic: A Longitudinal Mixed-Methods Study from a Cohort of HIV Clients in Uganda. AIDS Behav. 2023 Jul;27(7):2216-2225. doi: 10.1007/s10461-022-03953-6. Epub 2023 Jan 11.

Reference Type DERIVED
PMID: 36629972 (View on PubMed)

Saya U, MacCarthy S, Mukasa B, Wabukala P, Lunkuse L, Wagner Z, Linnemayr S. "The one who doesn't take ART medication has no wealth at all and no purpose on Earth" - a qualitative assessment of how HIV-positive adults in Uganda understand the health and wealth-related benefits of ART. BMC Public Health. 2022 May 27;22(1):1056. doi: 10.1186/s12889-022-13461-w.

Reference Type DERIVED
PMID: 35619119 (View on PubMed)

MacCarthy S, Mendoza-Graf A, Jennings Mayo-Wilson L, Wagner Z, Saya U, Chemusto H, Mukasa B, Linnemayr S. A qualitative exploration of health-related present bias among HIV-positive adults in Uganda. AIDS Care. 2023 Jun;35(6):883-891. doi: 10.1080/09540121.2021.2004298. Epub 2021 Nov 21.

Reference Type DERIVED
PMID: 34802344 (View on PubMed)

Wagner Z, Mukasa B, Nakakande J, Stecher C, Saya U, Linnemayr S. Impact of the COVID-19 Pandemic on Use of HIV Care, Antiretroviral Therapy Adherence, and Viral Suppression: An Observational Cohort Study From Uganda. J Acquir Immune Defic Syndr. 2021 Dec 15;88(5):448-456. doi: 10.1097/QAI.0000000000002811.

Reference Type DERIVED
PMID: 34757973 (View on PubMed)

Jennings Mayo-Wilson L, Devoto B, Coleman J, Mukasa B, Shelton A, MacCarthy S, Saya U, Chemusto H, Linnemayr S. Habit formation in support of antiretroviral medication adherence in clinic-enrolled HIV-infected adults: a qualitative assessment using free-listing and unstructured interviewing in Kampala, Uganda. AIDS Res Ther. 2020 Jun 8;17(1):30. doi: 10.1186/s12981-020-00283-2.

Reference Type DERIVED
PMID: 32513192 (View on PubMed)

Linnemayr S, Stecher C, Saya U, MacCarthy S, Wagner Z, Jennings L, Mukasa B. Behavioral Economics Incentives to Support HIV Treatment Adherence (BEST): Protocol for a randomized controlled trial in Uganda. Trials. 2020 Jan 3;21(1):9. doi: 10.1186/s13063-019-3795-4.

Reference Type DERIVED
PMID: 31900193 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1R01MH110350-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

R01MH110350

Identifier Type: NIH

Identifier Source: org_study_id

View Link

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Goals for Adherence with Low-cost Incentives
NCT05378607 ACTIVE_NOT_RECRUITING NA
Suubi+Adherence4Youth
NCT05600621 ACTIVE_NOT_RECRUITING NA